Page 1

● CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates First - Generation COVID - 19 vaccine program , CVnCoV O CUREVAC O the RNA people Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities Phase 2a trial in Peru and Panama assessing third booster vaccination at one and six month post second dose CureVac participating in broad UK trial evaluating different COVID - 19 vaccines as potential boosters at least three months following full primary vaccination First preclinical data of second - generation COVID - 19 vaccine candidate , CV2COV , demonstrates faster onset of antibody production and high variant cross - neutralization Rolling submission with Swissmedic initiated after filing of first data package Financials : cash position of € 1.50 billion as of March 31 , 2021 TÜBINGEN , Germany / BOSTON , USA May 26 , 2021 CureVac N.V. ( Nasdaq : CVAC ) , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ( " mRNA " ) , today announced business updates and financial results for the first quarter of 2021 . " The COVID - 19 reality has changed dramatically since the beginning of this year and is today characterized by the rapid spread of Variants of Concern as well as the emergence of new strains , which together have now all but supplanted the original virus strain that we fought throughout 2020 , " said Franz - Werner Haas , Chief Executive Officer of CureVac . " In this variant rich environment , we are convinced that our first - generation COVID - 19 vaccine candidate , CVnCoV , will make an important contribution to the pandemic vaccination programs , for which availability of potent vaccines is now more important than ever to stop the virus from evolving further . CVnCoV is in the final stage of clinical development in what we believe is one of the most diverse efficacy trials in terms of the range of virus variants . For CVnCoV , which we advance together with our partner Bayer , we are expecting the data readout from the pivotal Phase 2b / 3 trial in the second quarter , which will enable us to finalize our rolling submission with EMA . Our second - generation vaccine candidate , CV2CoV , is developed together with GSK and is planned to enter clinic trials in the third quarter of 2021. First preclinical data showed high potential for even lower doses that is expected to enable multivalent or combination vaccines to flexibly address different variants or different diseases in one vaccine . " " In the first quarter of 2021 , we were able to continue to build and strengthen our strong cash position with our first follow - on financing in February 2021 , raising $ 517.5 million in aggregated gross proceeds , " said Pierre Kemula , Chief Financial Officer of CureVac . " Together with our strategic partners Bayer and GSK , we are fully dedicated to create sustainable value with our COVID - 19 vaccine program - for the pandemic and beyond . This is further enabled by the ongoing ramp - up of our broad and integrated European manufacturing network as well as the RNA Printer , our autonomous and mobile manufacturing unit well suited to address pandemic preparedness . Build - up of our commercial infrastructure is progressing well as we prepare to potentially launch our first product and work toward our goal of becoming an integrated biopharma company . "